肝炎药物因治愈率和疗效而获奖

StephenW

Hepatitis drug wins award for cure rate and efficacyJoy Persaud
August 1, 2018

  Hepatitis C drug Ganovo won a top clinical research award due to its successful performance in a phase 3 trial.
The prestigious industry award was granted at the 15th Infectious Disease National Congress of the Chinese Medical Association.
It is the largest and most influential academic conference in China and attracted more than 2,000 experts and doctors.
The paper in question was one of 577 conference papers submitted this year and won the highest scientific merit: ‘extraordinary achievement’.
Non-cirrhotic patients on a treatment regimen of Ganovo, which is produced by Chinese biotech company, Ascletis, demonstrated a cure rate of 97% within 12 weeks of intervention.

Wei-Lai

Professor Wei Lai said, “This award showcased the outstanding recognition to Ganovo from the China Medical Association (CMA) and [key opinion leaders’] endorsement to China-driven self-innovation encouraged by the fast growth of the China bio-tech industry in recent years.
“As the first direct-acting anti-viral agent (DAA) developed and launched successfully by a domestic company in China, Ganovo has shown excellent efficacy, better safety and tolerability.
“I sincerely hope Ganovo will make a larger impact and significant contribution to the elimination of HCV disease in China.”
Ascletis focuses on the development and commercialisation of innovative drugs against hepatitis C virus (HCV), AIDS (HIV) and the hepatitis B virus (HBV). The company is currently running five programmes of antiviral drug discovery and development.
Hepatitis C is a virus that can infect the liver and, if untreated, can cause serious and potentially life-threatening damage to the liver over time, particularly because the disease is usually only detected once the organ is damaged.
The symptoms are muscle aches, high temperature, exhaustion, loss of appetite, abdominal pain and nausea.
The virus is spread via blood-to-blood contact, and in the UK, most hepatitis C infections occur in those who inject drugs or have done so in the past. Around half of those who inject drugs are thought to have the infection.
However, with modern treatments the infection can be cured and most sufferers will have a normal life expectancy. Around 215,000 people in the UK have hepatitis C.

StephenW

肝炎药物因治愈率和疗效而获奖
Joy PersaudJoy Persaud
2018年8月1日

丙型肝炎药物Ganovo因其在3期试验中的成功表现而获得了最高临床研究奖。

这项享有盛誉的行业奖项是在第15届中华医学会传染病大会上颁发的。

它是中国规模最大，最具影响力的学术会议，吸引了2000多名专家和医生。

该论文是今年提交的577份会议论文之一，并获得了最高的科学价值：“非凡成就”。

由中国生物技术公司Ascletis生产的Ganovo治疗方案的非肝硬化患者在干预后12周内治愈率为97％。
潍莱

潍莱

魏丽教授说：“这个奖项展示了中国医学会（CMA）对中国医学界的认可，以及[关键意见领袖]对中国生物技术产业快速发展所鼓励的中国自主创新的支持。最近几年。

“作为国内首家在中国成功开发和推出的第一种直接作用抗病毒剂（DAA），Ganovo具有卓越的疗效，更好的安全性和耐受性。

“我衷心希望Ganovo能为中国消除HCV疾病带来更大的影响和重大贡献。”

Ascletis致力于开发和商业化抗丙型肝炎病毒（HCV），艾滋病（HIV）和乙型肝炎病毒（HBV）的创新药物。该公司目前正在运行五个抗病毒药物发现和开发计划。

丙型肝炎是一种可以感染肝脏的病毒，如果不及时治疗，会随着时间的推移对肝脏造成严重的，可能危及生命的损害，特别是因为一旦器官受损，通常只能检测到这种疾病。

症状是肌肉酸痛，高温，疲惫，食欲不振，腹痛和恶心。

病毒通过血液与血液接触传播，而在英国，大多数丙型肝炎感染发生在那些注射毒品或过去曾经这样做的人身上。大约一半注射毒品的人被认为有感染。

然而，通过现代治疗，感染可以治愈，并且大多数患者将具有正常的预期寿命。英国约有215,000人患有丙型肝炎。